Epitalon

Table of Contents

1. What Epitalon Is
2. Where It Came From
3. How It Is Thought to Work
4. Laboratory and Animal Research
5. Human Studies of Epitalon and Epithalamin
6. What the U.S. Food and Drug Administration Found
7. The July 2026 Advisory Committee Vote
8. The October 2026 Health and Human Services Interim Policy
9. Safety Findings and Unknowns
10. What Is Not Known
11. Key Research Papers
12. Connections
13. Featured Videos

What Epitalon Is

A peptide is a short chain of amino acids, the same building blocks that make up proteins. Epitalon is a tetrapeptide, a chain of exactly four: alanine, glutamic acid, aspartic acid and glycine, in that order. In the standard three-letter code the October 2026 federal policy prints it as “H-Ala-Glu-Asp-Gly-OH,” and research papers often shorten it to its one-letter code. It is also spelled epithalon or epitalone. The U.S. Food and Drug Administration's 2026 presentation slides note that “Epitalon is a common name and not a USAN, INN, or IUPAC name,” meaning it has no official name under the United States, international or chemical naming systems, and its briefing counted inconsistent naming as a patient-safety risk, because a patient “may be dosed with a different bulk drug substance than the physician ordered.”

The agency's briefing describes it as “a synthetic peptide, which may be identified as the putative active component of a bovine pineal gland extract known as epithalamin.” The pineal gland is a pea-sized gland deep in the brain that makes the night-time hormone melatonin. The agency nevertheless treats the two as different substances: epithalamin “is a polypeptide complex extracted from the pineal gland,” while epitalon “is a tetrapeptide synthesized based on the study of the amino acid content of epithalamin.” Results obtained with epithalamin are therefore reported separately on this page.

Free base and acetate: two forms, two regulatory substances

Peptides can be made and sold in more than one chemical form. The free base is the peptide on its own; the agency lists it with the molecular formula C₁₄H₂₂N₄O₉, a molecular weight of 390.35 grams per mole and the Chemical Abstracts Service (CAS) registry number 307297-39-8. The acetate is the same peptide paired with one unit of acetate, the charged form of acetic acid (the acid in vinegar); the agency lists it at 450.40 grams per mole with registry number 307297-40-1, and the October 2026 policy gives the same weight. The active peptide is the same, but the two powders differ in weight, behaviour in water and the tests needed to confirm what they contain. The agency's briefing describes the free base as a white to off-white freeze-dried powder and states that, because of its limited solubility in water, “it may not be possible to compound epitalon (free base) injection at 3 mg/mL using water as the solvent,” which is one of the two strengths that had been proposed.

The U.S. Food and Drug Administration treats each form as a separate bulk drug substance, the raw active ingredient, usually a powder, from which a pharmacy prepares an injection or other product. For that reason its advisory committee voted on the free base and the acetate separately, and the October 2026 policy covers only the acetate.

Back to Table of Contents

Where It Came From

Epitalon grew out of a long programme of peptide research at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, the affiliation of its main developer, V. Kh. Khavinson. A long review he published in 2002, which refers to “three decades of studies,” describes how the institute first made “complex peptide preparations” from extracts of animal organs, including the pineal preparation epithalamin, and then, “based on the data about the amino acid compositions” of those extracts, designed short synthetic peptides meant to act on particular tissues. For the pineal gland and the retina of the eye, the review states, “a common tetrapeptide Ala-Glu-Asp-Gly (Epitalon) has been designed.” The review puts forward a “peptide theory of ageing,” the authors' proposal that ageing involves a loss of such regulatory peptides and that supplying them can restore function.

The date of first synthesis is uncertain. The U.S. Food and Drug Administration's briefing gives two different answers: in one place it says the free base was “first synthesized in the late 1980s,” and in another that epitalon “appears to have first been synthesized in 1999 due to the limited availability of calf pineal gland needed to produce epithalamin.” The earliest papers on it indexed in PubMed date from 2000, among them a study in fruit flies. In 2017 the St. Petersburg group reported detecting the same four-amino-acid sequence among the small peptides of the pineal extract by mass spectrometry, and concluded that the extract's effects are “determined by the effect of its component” peptide.

A literature from one main research group

A PubMed search on 14 November 2026 for “epitalon” or “epithalon” returned 144 records. Khavinson is an author on 89 of them, and 94 list Khavinson, V. N. Anisimov or both; Anisimov's group at the N. N. Petrov Research Institute of Oncology in St. Petersburg ran the long-term mouse studies described below. Much of this work appeared in Russian-language journals or in English translations of them. Work by unconnected teams is limited: a 2025 laboratory study from Brunel University London on telomeres, a 2015 laboratory analysis by Belgium's public health institute of products seized as illegal medicines, and reviews from Poland (2025) and the United States (2026). The 2026 U.S. review, which appraised the evidence by study design, size and “independent replication,” called epitalon “biologically active but clinically unproven.”

Back to Table of Contents

How It Is Thought to Work

Every mechanism below comes from cell-culture and animal experiments, and most from the developers' own laboratories. A 2025 review from the Medical University of Warsaw, after summarising them, stated that “it remains uncertain whether these are the sole mechanisms of action of this compound” and that “the quantity of physico-chemical and structural investigations of this peptide remains quite limited.”

• Melatonin and the body clock. In 2001 Khavinson and researchers from a primate institute in Sochi reported that epitalon stimulated evening melatonin production in old female rhesus monkeys; the U.S. Food and Drug Administration's briefing summarises their results as a more than 4-fold rise in evening melatonin and a fall of about 30% in evening levels of the stress hormone cortisol in the older animals. A 2003 study run in Paris, with the developers as co-authors, tested the peptide directly on pineal glands taken from young and old rats and found it “had no significant effect upon melatonin secretion whatever the age of the animals”; the authors concluded that it does not seem to play a role, at least in the laboratory dish, in controlling melatonin release. Background on the hormone is on the Melatonin and the Body Clock page.
• Telomeres and telomerase. Telomeres are protective caps on the ends of chromosomes that shorten each time a cell divides; telomerase is the enzyme that can rebuild them (see Telomeres: Why Cells Grow Old). In 2003 Khavinson's group reported that adding the peptide to human fetal fibroblasts (connective-tissue cells) grown in the laboratory switched on telomerase and lengthened telomeres. In 2025 a team at Brunel University London, unconnected with the developers, treated normal human epithelial cells and fibroblasts and two breast cancer cell lines. In the normal cells, telomeres lengthened in step with the dose, along with increased activity of the telomerase gene and enzyme; in the cancer cells telomeres also lengthened, through a different route called alternative lengthening of telomeres.
• Gene activity. The developers propose that short peptides of this kind interact with genetic material in the cell nucleus and change which genes are switched on. Their 2002 review suggests the peptide's effects are “mediated by transcriptional machinery common for the pineal gland and the retina.” This has been studied mainly by the same group.
• Oxidative stress. Papers from the group and its collaborators describe reduced markers of free-radical damage in fruit flies and rodents given the peptide; the Warsaw review groups these as antioxidant effects.

The telomere finding cuts both ways. Lengthening telomeres is the effect promoted for “anti-aging,” but cancer cells depend on keeping their telomeres long, and the U.S. Food and Drug Administration raised exactly this point (see Safety Findings and Unknowns).

Back to Table of Contents

Laboratory and Animal Research

The animal research is almost entirely from St. Petersburg and is almost uniformly reported as positive. Most experiments gave tiny doses, often around one microgram per mouse, by injection under the skin for five days each month over the animals' lifetimes. The U.S. Food and Drug Administration's comments on how far these studies can be relied on follow at the end of this section.

Lifespan in fruit flies

In a 2000 study, the peptide was added to the food of fruit flies only while they developed from egg to larva. The adult flies lived 11% to 16% longer than untreated flies, at concentrations the authors called “unprecedented low,” and the increase did not depend on the dose.

Lifespan and tumours in mice

• CBA mice, 2001. Female mice received 0.1 microgram under the skin for five consecutive days each month from the age of 6 months until they died. Compared with mice given salt water, treated mice lived 5.3% longer on average, kept their reproductive cycles longer, and had fewer spontaneous tumours, mainly lung adenomas, along with lower measures of free-radical damage.
• Swiss-derived SHR mice, 2003. Groups of 54 female mice received 1 microgram (about 30 to 40 micrograms per kilogram) five days a month from 3 months of age until death. Average lifespan, food intake and body weight did not change. The last 10% of survivors lived 13.3% longer, chromosome damage in bone marrow cells was 17.1% lower, total tumour numbers were unchanged, and leukaemia was six times less common than in controls. The authors wrote that the data suggest “the safety of its long-term administration in mice.”
• Mice bred to develop breast cancer, 2002. Female mice carrying the HER-2/neu gene (human epidermal growth factor receptor 2, a cancer-promoting gene) received 1 microgram five days a month from 2 months of age. Treated mice developed fewer and smaller breast tumours in total, their lung metastases were smaller though not fewer, and the tumours showed 3.7-fold lower activity of the HER-2/neu gene. In the same study, a second synthetic peptide from the same programme, the thymus-targeted two-amino-acid peptide lysine-glutamic acid, was followed by more breast cancers and earlier tumours than in untreated mice.

The U.S. Food and Drug Administration reviewed these mouse studies and wrote that “they should be interpreted with caution because: (i) each study used a fixed dose of epitalon ... and (ii) the three studies assessed the effects of epitalon only in female (not male) mice.” It found no standard two-year cancer studies.

Eye, monkeys and other models

In Campbell rats, which inherit a degeneration of the retina, the developers reported that the peptide preserved the retina's structure and electrical activity. In old rhesus monkeys it raised evening melatonin (see How It Is Thought to Work). Other papers from the group and its collaborators describe effects on immune cells, gut enzymes, kidney function and the thyroid in rodents and chickens. The agency's briefing found no animal study that measured sleep itself, the use it evaluated: in the monkey study, it noted, “the authors did not assess sleep behavior or electroencephalographic activity,” meaning brain-wave recordings.

Back to Table of Contents

Human Studies of Epitalon and Epithalamin

Human research on the synthetic peptide itself is thin, almost all of it from the developers and their collaborators, and none of it tests the use the U.S. Food and Drug Administration evaluated, insomnia. The agency's 2026 search of the medical literature found no publications on its effectiveness in patients with insomnia and no clinical studies of it given by injection under the skin, the route that had been proposed. A 2026 U.S. review concluded that human evidence “is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa,” and that “no adequately powered randomized trial has established therapeutic efficacy.”

• Retinitis pigmentosa, 2002. In a paper on retinitis pigmentosa, an inherited loss of the light-sensing cells of the retina, the developers reported that treatment gave “a positive clinical effect in 90% of the cases.” The agency describes the treatment as a parabulbar injection, given next to the eyeball. PubMed indexes the paper as a controlled clinical trial; its abstract does not state how many patients took part or how the effect was measured. The peptide received a U.S. orphan drug designation for retinitis pigmentosa on 2 September 2010, which, according to the agency's briefing, was “withdrawn/revoked on January 6, 2016.”
• Melatonin in elderly people, 2007. A Russian-language paper by the developers and Ukrainian and primate-research colleagues reported that both epithalamin and epitalon restored night-time melatonin release in old monkeys and elderly people, and, in the agency's summary of its abstract, described the preparations as having “no side effects” in elderly people. The agency noted that the paper did not provide the route, dosing, duration, number or characteristics of subjects, or how safety data were collected.
• Women working night shifts. The agency's briefing describes a study by Ivko and colleagues, published in English in 2021, as “a randomized, placebo-controlled study” of the peptide given under the tongue to 75 healthy women aged 40 to 50 who mainly worked night shifts, for 20 days. In the group with low melatonin output, the urinary breakdown product of melatonin, 6-sulfatoxymelatonin, rose 1.7-fold with the peptide; a 2020 Russian-language paper by the same five authors reports the same 1.7-fold rise and changes in the activity of body-clock genes in white blood cells. The agency noted that the publication “did not specify blinding,” that the study was short and small, that it “did not evaluate sleep outcomes,” and that the peptide was given under the tongue rather than by injection. Related conditions are on the Circadian Rhythm Sleep-Wake Disorders page.

No human pharmacokinetic study, that is, a measurement of how much of the peptide reaches the blood and how quickly it is cleared, has been published for any route. The agency found that a raised melatonin level by itself does not show benefit: “The potential therapeutic effect of changes in melatonin levels induced by these substances is unclear without a corresponding evaluation of clinical outcomes,” and its briefing adds that low melatonin levels “have not been consistently associated with insomnia in elderly adults.”

Studies of epithalamin, the pineal extract

Human studies also exist for epithalamin, the peptide extract from cattle pineal glands on which epitalon was modelled. The U.S. Food and Drug Administration considers them different substances, so these results are not evidence about the synthetic peptide. The two best-known human studies both list Khavinson as an author and were run with the Institute of Gerontology in Kyiv, Ukraine.

• Elderly people followed for 6 to 8 years, 2003. The authors report giving a thymus extract, epithalamin, or both to 266 elderly people during the first 2 to 3 years of observation. They report fewer acute respiratory illnesses and fewer signs of heart disease, high blood pressure, osteoarthritis and osteoporosis than in the control group, and a death rate 1.6 to 1.8 times lower in the epithalamin group. PubMed indexes the paper as a randomized controlled trial; the abstract does not say how participants were assigned to groups.
• Elderly heart patients followed for 12 years, 2006. In what the authors describe as a randomized study of elderly people with coronary heart disease and “accelerated aging of the cardiovascular system,” all of whom received standard treatment, 28% fewer people had died after 12 years in the group given courses of epithalamin, and cardiovascular deaths were half as common.

Both reports come from the developers' own collaboration. The U.S. Food and Drug Administration's briefing lists several epithalamin studies in its references but treats epithalamin as a different substance, so it did not count them as evidence for epitalon.

Back to Table of Contents

What the U.S. Food and Drug Administration Found

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, compound (prepare) a medicine for an individual patient's prescription without the drug going through approval. A bulk drug substance can be used under section 503A only if it has a United States Pharmacopeia or National Formulary monograph, is part of an approved drug, or appears on a list the agency builds by regulation, the “503A Bulks List.” The agency's briefing states that neither form of epitalon meets the first two, and neither is on the list. The full background is on the U.S. Food and Drug Administration Review of Compounded Peptides page.

The safety-risk category

According to the October 2026 federal policy, epitalon sat in the agency's “Category 2” of nominated substances with significant safety risks “from September 29, 2023, until April 22, 2026.” It now appears in the agency's table of substances “nominated but withdrawn,” and that entry still notes possible immunogenicity from aggregation and peptide-related impurities, and that no safety information had been identified for the proposed route. Immunogenicity is the ability of a substance to provoke an immune reaction, such as antibodies against the peptide; peptides that clump together (aggregate) or carry closely related manufacturing impurities can make such a reaction more likely.

The 2026 briefing, criterion by criterion

The nominations, which proposed injections under the skin at 10 milligrams per millilitre and 3,000 micrograms per millilitre, had been withdrawn; the agency evaluated both forms anyway, “on its own initiative,” for the July 2026 advisory committee meeting (briefing document, dated 12 May 2026). It evaluated one use, insomnia. Other proposed uses, among them anti-aging, longevity, lengthening telomeres, deeper sleep, delaying dementia and skin health, were not evaluated “because the nominations did not include sufficient information.” It weighed the four criteria set by a 2019 rule:

• Physical and chemical characterization. Both forms were “considered not well-characterized,” because of inconsistent naming and missing or inadequate data on identity, purity and quality. No certificate of analysis for the free base was in the nominations, and those found online gave only purity results, with no information on impurities. The acetate's certificate listed purity of at least 98%, with a result of 99.5%, and allowed up to 1.0% of any single impurity, but “no information regarding the nature of individual impurities” and no test for microbes or bacterial endotoxins was given.
• Safety. The agency concluded that “there are no clinical data to support the safety of epitalon (free base) or epitalon acetate when used in humans” (details under Safety Findings and Unknowns).
• Effectiveness. The agency found “a lack of evidence to support the effectiveness” of either form for insomnia, which it described as a disorder that “increases the risk for serious conditions.” It noted that the 2017 chronic-insomnia guideline of the American Academy of Sleep Medicine does not mention epitalon, and listed several classes of approved insomnia drugs, including melatonin receptor agonists and orexin receptor antagonists.
• Historical use. The nominators submitted 23 articles, “but none of the articles discussed the use of a compounded formulation of epitalon.” The agency cited a U.S. Attorney's press release about a pharmacy that compounded and distributed products containing epitalon from October 2018 to April 2020; its briefing refers to a guilty plea and its slides state that the pharmacy and its owner were sentenced for unlawful distribution of compounded drugs. It found that the peptide is “marketed online by several wellness clinics and concierge medicine practices for use as an anti-aging agent,” that sellers label it “for research use only,” and that no outsourcing facility had reported compounding it. It judged the data “too limited” to understand historical use.

The briefing concluded that “a balancing of the criteria weighs against” listing either form, and the agency's written proposal was that “epitalon (free base) and epitalon acetate NOT be included on the 503A Bulks List.”

Status outside the United States

The agency's briefing states that epitalon “is not recognized in either the European (11.8th edition) or Japanese (18th edition) Pharmacopeia,” that there are no approved products containing it in Canada, Australia, the United Kingdom, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and that no product containing it has been authorized by the European Medicines Agency. Its slides add that it was not found in “any of the National Medical Registries searched.” One nomination answered the agency's question on recognition abroad with “Russian Pharmacopoeia”; the agency's review did not address that claim, and no primary Russian source was checked for this page.

Back to Table of Contents

The July 2026 Advisory Committee Vote

The agency's Pharmacy Compounding Advisory Committee, a panel of outside experts, met on 23 and 24 July 2026 to consider seven peptides. Epitalon was taken on 24 July, for insomnia. The committee voted on two questions: whether to place the free base on the 503A Bulks List, and whether to place the acetate on it. A yes vote meant recommending that the agency list the substance.

• Free base: 7 yes, 4 no, 1 abstention — recommended for the list.
• Acetate: 7 yes, 4 no, 1 abstention — recommended for the list.

Both counts were read aloud “for the record” by the agency's Designated Federal Officer during the agency's own broadcast of the meeting, whose addresses are given in the agency's webcast information document. The final meeting roster lists 12 members eligible to vote on this topic, fewer than for any other peptide that week, and each tally adds up to exactly 12. Some news reports printed the result as 7–5 with one abstention, which would be 13 votes. As of 14 November 2026 the agency had posted no minutes, summary or transcript of the meeting, so the broadcast remains the record of the vote.

The Regulatory Affairs Professionals Society's news service reported the reasons two members gave: one who voted no cited “poor characterization” and a “potential risk with carcinogenicity,” while one who voted yes said that “a physician and pharmacist are key to judging the risk.”

Advice against the agency's own staff proposal

The majority went against the written proposal of the agency's staff, which was that neither form be listed. The vote is advice, not a decision. The agency's meeting page says advisory committees “make non-binding recommendations,” which the agency “generally follows” but “is not legally bound” to follow. During the meeting an agency participant said, according to the broadcast's automatic captions: “So we made recommendations that you heard today and that were in the memos, but those weren't final decisions. So the final decisions would come out through rulemaking.”

Between the meeting and 14 November 2026 the agency published no proposed or final rule on epitalon, and its Category 2 page, still dated 22 April 2026, kept the peptide in the withdrawn table with its safety note unchanged. The same committee recommended Body Protection Compound-157 (BPC-157), Lysine-Proline-Valine (KPV) and Thymosin Beta-4 Fragment (TB-500) by 8–6–1, Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) by 7–5–2 and Semax by 8–5–1, and voted against only one of the seven, emideltide (delta sleep-inducing peptide), by 6–7–1. All the votes are compared on the Peptides hub.

Back to Table of Contents

The October 2026 Health and Human Services Interim Policy

On 30 October 2026 the Federal Register published a notice of availability for the “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 Federal Register 68526, docket HHS-OASH-2026-0496). It had been filed for public inspection on 28 October. The notice calls it a “draft” and also “this interim policy”; the policy document itself uses only “interim.” The notice is signed by Robert F. Kennedy, Jr., Secretary of Health and Human Services; the policy document carries no signature or date, and neither states an effective date. The full policy is described on the peptide compounding enforcement discretion page.

Enforcement discretion means a government agency states that it does not intend to take action against certain activity that it could act against under the law. The policy says that, until each peptide is addressed in a final rule, the department “does not intend to take action” against a state-licensed pharmacy, federal facility or licensed physician compounding with one of six listed peptides, when ten conditions are all met. Epitalon is second on the list, after Body Protection Compound-157.

What it covers for this peptide

• Form: the acetate only, printed in the policy's Appendix B as “H-Ala-Glu-Asp-Gly-OH·CH₃COOH” with a molecular weight of 450.40 grams per mole. The free base is not covered.
• Routes: the policy states that enforcement discretion for epitalon acetate is appropriate for “subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses,” meaning injection under the skin or into muscle. No oral, nasal or skin form is covered. Epitalon is the only one of the six peptides whose route limit carries the “intermittent courses” wording; the sentence does not state how long a course is or how often one may be repeated.

The conditions in plain words

1. The peptide is on the policy's list (Appendix A).
2. It has the identity and route limits set out in Appendix B.
3. The raw powder comes from a facility registered with the U.S. Food and Drug Administration, with a valid certificate of analysis showing tests for identity, purity, strength and contaminants such as bacterial endotoxins, heavy metals, microbes and impurities.
4. The original manufacturer is registered, follows current good manufacturing practice, and is named with its address on the certificate; a reseller has to have checked the manufacturer and its certificate.
5. The compounder reports serious adverse events, whether or not they seem drug-related, and product quality problems to the agency's MedWatch program and to the states involved, along with what was compounded and from whose raw material.
6. The label reads “This is a compounded drug product. Not for resale.”
7. The product contains only one listed active ingredient, so that side effects can be traced to a single substance.
8. Any oral form comes with documentation that it is adequately absorbed in humans (this does not arise for epitalon, which is covered only as an injection).
9. The only device packaged with the product is a syringe cleared by the U.S. Food and Drug Administration.
10. All other legal requirements still apply, including a prescription for an individual patient and the ban on preparing drugs under insanitary conditions.

What it does not do

• It is not an approval. The policy states that compounded drugs are not approved by the U.S. Food and Drug Administration, which means the agency does not review their safety, effectiveness or quality before they are marketed.
• It is not a listing. Epitalon is not added to the 503A Bulks List; the policy runs only while that list is developed through rulemaking, and the Federal Register notice says future rules “may propose adding some or all of these peptides.”
• It is not binding. The notice states that it “does not establish any rights for any person” and is not binding on the department or the public.
• It is not permanent. It ends for each peptide when a final rule includes or excludes it, and the department may revisit it if “a safety signal or product quality issue arises.”
• It names only three kinds of compounder. Larger outsourcing facilities under section 503B are not among them, although the document contains no sentence that excludes them in so many words.

The reasons the policy gives

The policy states that the advisory committee “voted in favor of inclusion,” and that the agency's Center for Drug Evaluation and Research “recommended against listing either form.” It gives three reasons for including epitalon anyway: that historical use “is now documented and quantified”; that the characterization record has “materially changed” because lot-specific certificates from registered facilities now supply test results the agency had found missing; and that the center's safety concerns about the peptide are “mechanistic rather than observed.” More broadly, it says the policy “will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers” and offer patients “a more controlled alternative,” and that it “advances patient choice and freedom while appropriately protecting patient safety.” The policy cites no named adverse event or usage data set.

Status on 14 November 2026

Comments closed at 11:59 p.m. Eastern Time on 13 November 2026, two weeks after publication. The Federal Register's records counted about 289 comments received, of which 115 had been posted publicly on the government's regulations website. No final version of the policy and no statement about it on the U.S. Food and Drug Administration's website had been found, and epitalon was still not on the 503A Bulks List.

Back to Table of Contents

Safety Findings and Unknowns

Reports to the agency

A search of the agency's adverse event reporting system through 8 December 2025 found no reports for epitalon, and a search of its complaint system for foods and supplements through 5 December 2025 found no cases. The agency's slides add that “the lack of reports for epitalon does not imply that the substance is safe or lacks toxicities.” Voluntary reporting systems cannot show how often a problem happens.

No human safety studies

The agency's briefing states that neither the nominations nor its own search of the medical literature identified any clinical study assessing the safety of either form of epitalon in humans. The night-shift study “did not report safety data,” and the 2007 report of “no side effects” in elderly people gave no route, dose, duration, number of subjects or method of collecting safety data. The agency concluded that there is “a lack of important information regarding the use of these substances administered subcutaneously, including whether the drug would cause harm if administered to humans.”

Immune reactions and impurities

The agency wrote that it “cannot rule out the potential for immunogenicity” from impurities and peptide clumps, and that injection under the skin, the proposed route, is generally linked with a higher risk of immune reactions than other injection routes. The certificate it saw for the acetate did not identify the individual impurities that could each make up as much as 1% of the powder, and included no test for microbes or bacterial endotoxins.

The cancer question

The mouse studies reported fewer tumours in treated animals, and the developers described them as showing safety in long-term use in mice. The U.S. Food and Drug Administration reached a different reading from the same mechanism. It wrote that “chronic continuous exposures to epitalon, by virtue of upregulating telomerase and extending telomere lengths beyond the upper boundary limits for cells to become immortalized and cancerous, could result in carcinogenicity,” and that “from the mechanistic standpoint, epitalon has the potential to be carcinogenic.” A 2019 review from Johns Hopkins University, cited by the agency, describes evidence that inherited variants which lengthen telomeres are strongly associated with cancer risk, in particular melanoma and chronic lymphocytic leukaemia. The 2025 Brunel University London study found that the peptide lengthened telomeres in breast cancer cell lines as well as in normal cells. The agency judged the animal studies “too limited in scope and duration” to settle the question, and the October 2026 policy describes the concern as “mechanistic rather than observed.” No study has tested the effect in people with existing cancers.

Other toxicology

The agency identified no standard repeat-dose, reproductive or developmental toxicity studies and no studies of how animals absorb and clear the peptide, apart from a rabbit study using a fluorescent label whose signal, the agency wrote, may not have come from the peptide itself. Two chromosome-damage tests in mice found no damage, but each used a single fixed dose, which the agency described as a limitation.

Products sold for “research use”

The peptide is widely sold online labelled “for research use only.” In 2015 Belgium's Scientific Institute of Public Health reported identifying epitalon in two illegal pharmaceutical preparations. The October 2026 policy describes research-use-only peptides from foreign manufacturers as posing a safety risk to patients in the United States. In August 2026 the U.S. Food and Drug Administration sent warning letters to five online peptide sellers, finding that products labelled “research use only” were intended for human use; those five letters did not name epitalon. No published laboratory survey of the content and purity of epitalon products sold online in the United States was found in PubMed when this page was written.

Back to Table of Contents

What Is Not Known

• Whether epitalon helps any human condition. No study has measured its effect on sleep, the one use the U.S. Food and Drug Administration evaluated, and the human studies that exist are small, short and mostly measure melatonin.
• Whether it affects ageing or lifespan in people. The lifespan findings come from fruit flies and mice; the human mortality studies used epithalamin, a different substance.
• How much reaches the blood and tissues in people, and for how long. No human pharmacokinetic data exist for any route.
• Whether long-term or repeated use raises the risk of cancer through telomere lengthening, and whether it provokes immune reactions. Neither has been studied in humans.
• How far the findings hold up outside the St. Petersburg group and its collaborators, who produced most of the research.
• What products sold online actually contain.
• What the agency will decide. As of 14 November 2026 no proposed or final rule had been published, the advisory committee's vote was advice only, and the interim policy was a draft with its comment period just closed.

Decisions about unapproved and compounded medicines belong with a clinician who knows the person's history and what the evidence does and does not show.

Back to Table of Contents

Key Research Papers

1. Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000;120(1-3):141-9. PubMed PMID: 11087911
2. Anisimov VN, Khavinson VK, Mikhalski AI, Yashin AI. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech Ageing Dev. 2001;122(1):41-68. PubMed PMID: 11163623
3. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PubMed PMID: 12374906
4. Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. PubMed PMID: 12209581
5. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. PubMed PMID: 12195242
6. Djeridane Y, Khavinson VKh, Anisimov VN, Touitou Y. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-GLy) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Invest. 2003;26(3):211-5. PubMed PMID: 12809170
7. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PubMed PMID: 12937682
8. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PubMed PMID: 14501183
9. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. PubMed PMID: 14523363
10. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-9. PubMed PMID: 17426848
11. Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015;7(3):259-64. PubMed PMID: 25535022
12. McNally EJ, Luncsford PJ, Armanios M. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129(9):3474-3481. PubMed PMID: 31380804
13. Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA. [AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging]. Adv Gerontol. 2020;33(3):429-435. PubMed PMID: 33280326 (article in Russian)
14. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. PubMed PMID: 40141333
15. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PubMed PMID: 40908429 (a correction notice was published in the same journal in November 2025)
16. Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci. 2026;27(19):8922. PubMed PMID: 42884164

PubMed Topic Searches

1. PubMed: Epitalon
2. PubMed: Epitalon and telomerase
3. PubMed: Epitalon and melatonin
4. PubMed: Epithalamin
5. PubMed: peptide drugs, immunogenicity and impurities

Back to Table of Contents

Connections

• Peptides — the six peptides in the 2026 compounding policy
• U.S. Food and Drug Administration Review of Compounded Peptides — the 2026 review and advisory committee
• Peptide Compounding Enforcement Discretion — the October 2026 interim policy
• Peptide compounding news, 14 November 2026 — the news article
• Drugs — every drug page on the site
• Melatonin — the pineal hormone most epitalon studies measure
• Insomnia — the use the agency evaluated
• Retinitis Pigmentosa — the subject of a 2002 study and a revoked orphan designation
• Circadian Rhythm Sleep-Wake Disorders — night-shift work and the body clock
• Telomeres: Why Cells Grow Old — the chromosome caps epitalon is reported to lengthen
• Blackburn, Greider and Szostak — the discovery of telomerase
• Longevity and Healthy Aging — the claims under which epitalon is sold
• Alanine — first of the peptide's four amino acids
• Glutamic Acid — second amino acid
• Aspartic Acid — third amino acid
• Glycine — fourth amino acid

Back to Table of Contents

Featured Videos